LEST THE REMEDY AGGRAVATE THE MALADY by Kuruvilla, K.
Indian J. Psychiat., 1994,36(1), 1-3. 
&\ 
EDITORIAL 
LEST THE REMEDY AGGRAVATE THE MALADY 
While the contribution of psychopharmacologi-
cal agents in controlling the disturbing symptoms of 
many psychiatric disorders and in improving the 
quality of life of the persons suffering from the 
disorders cannot be disputed, it is also true that these 
agents, as in the case of drugs used in the treatment 
of any other group of disorders, may also produce 
uncomfortable and at times even dangerous adverse 
effects. These adverse effects invariably influence 
the patients compliance with a medication and the 
physician's confidence to prescribe it. In some cases 
the observation of adverse effects has led to the 
premature withdrawal of some otherwise useful 
drugs from the market. 
It is well known that adverse effects which are 
observed in the early period of the usage of a drug 
get widely publicized, but as more experience in its 
use is gained, these adverse effects are understood 
to be not as frequent or as dangerous as initially 
thought. The early reports of cholestatic jaundice 
with chlorpromazine and the unconfirmed fear about 
fluoxetine increasing suicidal ideation are examples 
of this. It is also true that as experience with a 
pharmacological agent accumulates, the clinician 
and researcher become more aware of the true 
prevalence and significance of certain adverse ef-
fects which were initially unknown, or considered 
insignificant. The awareness about the 
teratogenicity of lithium and the occurrence of tar-
dive dyskinesia and neuroleptic malignant 
syndrome with most anti-psychotics, are examples 
of this type of problem. Thus, as we survey the 
history of most pharmacological agents and for that 
matter, most treatment methods not only in 
psychiatry but in medicine in general, we find that 
our attitude towards a therapeutic modality goes 
through different phases. 
The first is a phase of excitement where exag-
gerated claims are made about the efficacy and 
safety of the method, resulting in the widespread use 
of the method (often enhanced by the consumers 
demand for it based on sensational reports in the lay 
press), in many conditions whether indicated or not. 
This is followed by a phase of disillusionment when 
the treatment method is found to be incapable of 
doing all what was expected of it and reports about 
its undesirable effects gradually accumulate, result-
ing in its total rejection and non-availability even to 
those who could have been benefitted by it. The third 
phase is a period of reassessment and revaluation 
of the true benefits and disadvantages of the treat-
ment modality based more on hard data and less on 
emotion and expectation. This leads to the final 
phase of acceptance, (albeit qualified), when a 
balance between unfounded optimism and un-
qualified rejection is struck. It is the responsibility 
of the clinician / researcher to hasten the process of 
any method of treatment reaching this final phase, 
through documentation of his observations. We are 
also endowed with the responsibility of enabling our 
patients and their families to make the right choices 
regarding treatment by presenting adequate infor-
mation to them about available methods of treatment 
and also of taking steps to prevent further harm when 
the negative effect of a treatment method comes to 
our notice. 
The lay public as well as uninformed profes-
sionals tend to believe that the occurrence of adverse 
or negative effects is a problem which occurs only 
in the case of pharmacological agents or physical 
methods of treatment like electroconvulsive 
therapy. The fact that psychosocial methods of treat-
ment also can adversely affect a patient and / or his 
family is often ignored. Hadley and Strupp (1976) 
reported that psychotherapists themselves admitted 
that 3% to 6% of their patients became worse with 
therapy. Buckley et al (1987) found that 21% of 
psychotherapists who completed personal 
psychotherapy or psychoanalysis, ielt that the 
therapy had certain harmful effects on some aspects 
of their lives. The negative effects of psychotherapy 
on the clients personal, social or family life are found 
to correlate with specific characteristics of the 
patient, the therapist and the technique employed. 
Recent workers in this area have our attention to the 
potential for financial exploitation (Book. 1991) 
sexual exploitation (Appelbaum &Jogcrson. l°9l), 
emotional exploitation (Rosenbloom, 1992) and the 
possibility of the psychotherapeutic relationship 
being used as an instrument of coercion in political 
or religious matters (Alderdice and Alderdice, 
1993). 
A new dimension to the possible adverse effects 
of psychotherapy was added by Kingdom et al 
(1986) who reported that a patient of theirs who 
underwent cognitive therapy for unipolar depression 
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switched to hypomania. Since supportive 
psychotherapy, wherein suggestions and advice are 
given to the patient, is perhaps the most widely 
practiced psychotherapeutic technique in India, I 
believe, we have to be particularly conscious about 
the possibility of the negative effects of treatment. 
We should be humble enough to accept the fact that 
the possession of an M.D. or Ph.D. does not auto-
matically confer on us the wisdom to provide the 
answers to all life's problems or the right to impose 
our views on the client; neither does it justify our 
propensity to dispense advice liberally using the 
excuse that the "Guru Chela" style of 
psychotherapeutic relationship has been advocated 
as the most appropriate one for our culture. 
Some of the articles in this issue of the journal 
invite our attention to this special responsibility of 
the psychiatrist to his patient. Dr. Agarwal's 
presidential address on "Ethics in Psychiatry" draws 
our attention to the ethical issues involved in the 
different aspects of psychiatric practice, including 
the ethical standards to be followed in the choice of 
various treatment methods. He rightly emphasizes, 
"treatment decisions should include not only the 
symptomatic recovery, but also increase the 
patient's ability for relating socially for gainful 
employment and ultimately personal happiness". 
While the usefulness of antipsychotics in the 
treatment of various psychotic disorders is unques-
tionable, the emergence of tardive dyskinesia has 
become a major problem especially because the 
effectiveness of currently available methods for its 
treatment is limited. Datta et al report that 25.5% of 
their patients who were treated with antipsychotics 
for three months or more developed tardive dys-
kinesia and that age, total antipsychotic dosage and 
duration of antipsychotic exposure positively corre-
lated with the occurrence of persistent tardive dys-
kinesia. 
These findings should once again remind us of 
the axiom that the use of antipsychotics should be 
limited to the smallest possible effective dosage for 
the shortest possible time. The high prevalence of 
tardive dyskinesia reported in research studies in 
contradistinction to his observation in regular fol-
low-up clinics, just goes to prove the point that 'what 
the mind does not know the eye does not see'. Every 
clinician should therefore be alert to the risk of his 
patient developing tardive dyskinesia while on an-
tipsychotics, because early detection and reduction 
of the medication are helpful in reversing it in about 
8% of the victims. 
The newer antidepressants, especially fluoxetine, 
have been hailed as miracle drugs and advocated for 
everything ranging from post traumatic stress disor-
der to premature ejaculation. Though fluoxetine is 
free from the anticholinergic effects which make 
tricyclic antidepressants unacceptable to many 
patients, it is well documented that its use can be 
associated with side effects like nausea, headache, 
nervousness, insomnia, anxiety, akathisia and 
seizures (Cooper, 1988). In this issue, Andrade 
reports a case where treatment of depression with 
fluoxetine resulted in vascular headache which 
necessitated concurrent use of propranolol. As with 
the use of tricyclic antidepressants and monoamine 
oxidase inhibitors, manic switch is reported with 
fluoxetine also. Damodaran et al describe a patient 
with leukoencephalopathy who when treated with 
fluoxetine for depressive symptoms, switched to 
mania. 
The report by Srinivasan et al about a patient who 
developed manic symptoms following hyp-
notherapy for depression is a valuable addition toour 
understanding that the potential for adverse effects 
is not only inherent in physical methods of treatment 
but also in psychological methods. 
The implications of the short and long term ad-
verse effects of psychiatric treatment methods are 
important not just to the psychiatrist, but also to 
everyone involved in the care of the mentally ill. As 
we develop newer strategies to reach the unreached, 
like training medical officers, health assistants and 
multipurpose workers in the detection and manage-
ment of mental illness in the community (as Naik et 
al and Nagarajiah et al report in this issue), we should 
also be aware of the limitations of such programs, 
such as the relatively limited attention being paid to 
the detection and management of adverse effects. It 
is hoped that as these training programs get well 
established and refined, strategies to deal with these 
problems also will be further developed. 
Our responsibility, as therapists using powerful 
pharmacological and psychological methods of 
treatment, which can lead to both beneficial and 
harmful effects on our patients, can be summarized 
in the words of Sidney Crown (1983) - "Every 
treatment from aspirin to steroids and psychotropics 
to psychotoxics, if it is effective inevitably has both 
curative and unwanted side effects. The latter must 
relate to the patient selected for treatment, to the 
condition treated and to the competence or otherwise 
of the person administering the treatment. Unwanted 
effects should be recognized, their sources spelled EDITORIAL 
out and strategies suggested as to how they might be 
overcome". 
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